CompanyVRXA VRXAWNasdaqZurich

Veraxa Biotech AG - Post de-SPAC

Veraxa Biotech develops conditionally active T cell engagers (BiTAC-TCEs), bispecific antibody-drug conjugates (bsADCs), and BiTAC-format antibodies for cancer.

Stories only

SEC EDGAR ClinicalTrials.gov veraxa.com

424B3Sep 4Latest SEC filing

Sep 4Latest story

September 2026

Veraxa Biotech names Raju Willener as new CFO

Sep 4PeopleVeraxa Biotech AG - Post de-SPAC

August 2026

Veraxa Biotech completes SPAC merger, registers resale of over 145 million shares

Aug 10FinancingVeraxa Biotech AG - Post de-SPAC